196results about How to "Reduce fibrosis" patented technology

The present invention relates to the use of a gene transfer product to reduce hyperplastic connective tissue growth after tissue trauma or implantation of a medical device. The present invention also relates to a medical device with improved biological properties for an at least partial contact with blood, bodily fluids and/or tissues when introduced in a mammalian body, which device comprises a core and a nucleic acid, encoding a product capable of leading to production of extracellular superoxide dismutase present in a biologically compatible medium. Said nucleic acid encodes a translation or transcription product, which is capable of inhibiting hyperplastic connective tissue growth and promoting endothelialisation in vivo at least partially on a synthetic surface of said core. The present invention also relates to a method of producing a medical device according to the invention.

Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).

A crosslinkable macromer system and related methods of preparing the system and using the system in the form of a crosslinked matrix between a tissue site and an implant article such as a tissue implant or on the porous surface of a prosthetic device. The macromer system includes two or more polymer-pendent polymerizable groups and one or more multifunctional initiator groups. The polymerizable groups and the initiator group(s), when polymer-pendent, can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility. A macromer system of the invention can be used as an interface between the tissue site and implant article in a manner sufficient to permit tissue growth through the crosslinked matrix and between the tissue site and implant. In a preferred embodiment, polymers with pendent polymerizable groups, for use in the macromer system, are prepared by reacting a polysaccharide polymer with a reactive moiety in an organic, polar solvent such as formamide.

Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin are disclosed. In particular, the invention relates to formulations comprising apelin encapsulated in liposome nanocarriers conjugated with polyethylene glycol (PEG) and their use in treatment of cardiovascular and pulmonary diseases and disorders. Encapsulation of apelin in PEG-conjugated liposomes significantly enhances efficacy, improves cellular uptake of apelin, and allows for sustained and extended release of apelin under physiological conditions.

A crosslinkable macromer system and related methods of preparing the system and using the system in the form of a crosslinked matrix between a tissue site and an implant article such as a tissue implant or on the porous surface of a prosthetic device. The macromer system includes two or more polymer-pendent polymerizable groups and one or more initiator groups (e.g., polymer-pendent initiator groups). The polymerizable groups and the initiator group(s), when polymer-pendent, can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility. A macromer system of the invention can be used as an interface between the tissue site and implant article in a manner sufficient to permit tissue growth through the crosslinked matrix and between the tissue site and implant. In a preferred embodiment, polymers with pendent polymerizable groups, for use in the macromer system, are prepared by reacting a polysaccharide polymer with a reactive moiety in an organic, polar solvent such as formamide.

As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.

The invention discloses a silicosis treatment aerosol containing a human mesenchymal stem cell exosome extract and a preparation method thereof, wherein the main component of the aerosol is the high-concentration mesenchymal stem cell exosome extract. The mesenchymal stem cells can secrete various cell factors in the culture process, and the cell factors can penetrate into the basal layer of an inner membrane, promote tissue differentiation of the inner membrane, angiogenesis and growth of granulation tissues, promote regeneration and repair of damaged skin tissue structures, reduce generation of scar connective tissues and reduce bacterial infection and inflammatory reaction of wound surface tissues. According to the aerosol and the preparation method thereof, a method of continuous starvation of the mesenchymal stem cells is adopted, a high-concentration human mesenchymal extract can be obtained in a short period of time, and a big amount of stem cell exosomes can be separated from the mesenchymal extract by an exosome extractor. The aerosol containing the high-concentration mesenchymal stem cell exosome extract disclosed by the invention is suitable for the restoration and treatment of silicosis.

The invention discloses single-decorative polietilenglicol insulin and making method with molecular weight at 6550-10800, which comprises the following steps: dissolving insulin in the acetate buffer with pH value at 3.0-5.0; adding mPEG-aldehyde and NaBH3CN; stirring; adding small-molecular amino acid to terminate reaction; dialyzing; condensing in the SP Sepharose FF chromatographic column; proceeding gradient elution through buffer with NaCl; collecting peak-3 eluent; condensing; dialyzing; freezing; drying to obtain PheB1-PEG-insulin.

The invention discloses a method for processing squid surimi. The method comprises a tenderizing step between a common cutting step and a blending step, wherein the tenderizing step comprises the processes of: adding water to soak the cut sleeve-fish strips, adding protease containing papain and flavourzyme to form compound protease according to the ratio of 500-1000 U/g of sleeve-fish strips; carrying out enzymolysis for 60-120 minutes when the pH is 6.5-7.5 and the temperature is 50-60 DEG C; and taking out the sleeve-fish strips, and then processing for 30-50 minutes when the ultrasonic power is 20-100 kHz. The tenderized squid surimi is fine and smooth in tissue, tender in mouthfeel, good in gelation ability and high viscosity; and the product does not easily crack.

The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-beta. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-beta in a living organism.

The invention discloses a medicine for treating chronic renal failure and a preparation method thereof. The medicine for treating chronic renal failure comprises bulk pharmaceutical chemicals, namely rehmanniae praeparatum, fructus corni, Indian buead, astragali radix and rhizoma atractylodis macrocephalae which are proportionally processed and prepared into granules. The medicine for treating chronic renal failure provided by the invention has functions of replenishing qi, nourishing kidney, invigorating spleen, resolving stasis, detoxing and removing turbidity, and can be used for treating the diseases such as early-stage and middle-stage chronic renal failure, spleen and kidney deficiency of syndrome differentiation of chronic kidney disease, blood stasis and obstruction, toxin and turbidity accumulation and the like.

The invention discloses pulse ultrasound treatment equipment for male erectile dysfunction.The pulse ultrasound treatment equipment comprises a master control device, a micro-control system and a treatment probe.The treatment probe comprises an ultrasound generator.The master control device sends control signals to the micro-control system, the micro-control system converts the control signals into control instructions and sends the control instructions to the ultrasound generator, and the ultrasound generator generates corresponding ultrasound according to the control instructions.The pulse ultrasound treatment equipment can generate the ultrasound for therapeutic use, treatment is conducted in vitro in a non-intrusive mode, pain brought to a patient by an operation is avoided, and harm of medicine to the human body of dependence of the human body on the medicine are avoided.The low-intensity pulse ultrasound can promote neovascularization, proliferation of cavernous body smooth muscle cells and eNOS and nNOS expression, improve blood flow of the penis, lower a TGF-beta1/Smad/CTGF signal channel and relieve fibrosis of the penis, the pathological change of the erection organ is improved accordingly, and finally the erection function of the penis is improved.

Macrodevices containing a micro-fabricated body having at least one or multiple compartments and a porous membrane, methods of making and using thereof, are described. The one or multiple compartments encapsulate one or more cells that secrete a therapeutic agent in cell-based therapy. The porous membrane provides immunoprotection the encapsulated cells. Further, the surface of the macrodevices is chemically modified using polymers and/or small molecules, reducing fibrosis of the macrodevices, thereby allowing in vivo delivery of the secreted therapeutic agents for extended periods of time.

Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGFβR1, TGFβR2, TNKS, TNIK, or mTOR.

Disclosed herein are formulations of nintedanib and salts thereof, indolinone derivative compounds and salts thereof for aerosolization and use of such formulations for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. Formulations and delivery options described herein allow for efficacious local delivery of nintedanib or a indolinone derivative compound or salt thereof. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that benefit by reformulation and inhalation administration.

The invention discloses application of carnosol as an inhibitor of inflammasomes. The carnosol has inhibitory effects on various inflammasomes, is a broad-spectrum inhibitor of inflammasomes, and is used for developing drugs for treating acquired inflammatory diseases and autoimmune diseases.

The invention discloses applicationof let-7c/let-7d in intrauterine adhesion and/or thin endometriumdiagnosis and treatment. It is discovered that for an intrauterine adhesion patient, let-7c/let-7d expression in the endometrium is remarkably reduced. In-vitro experiments show that after the let-7c/let-7d is reduced, fibroses endometrial epithelium cells are increased. In-vivoanimal experiments show that by supplementing the let-7c/let-7d, the endometriumfibrosis degree of an endometriumfibrosis mouse is remarkably reduced. Therefore, the let-7c/let-7d possiblyplay an importanteffect in the aspects of intrauterine adhesion and/or thin endometriumdiagnosis and treatment, and can be used for preparing medicine for treating intrauterine adhesion and/or thin endometriumdiagnosis and treatmentor preparing medicine for treating other diseases related to uterusfibrosis.

The present invention relates, in general, to fibroproliferative disorders, and, in particular, to a method of treating, preventing or reducing fibroproliferative disorders by administering to a mammal in need a composition comprising pharmacologically effective doses of a cytokine modifier, such as tranilast or pirfenidone, and an anti-oxidant which is a precursor of glutathione, such as N-acetyl-cysteine, or their pharmaceutically acceptable derivatives, salts, metabolites, or structural or functional analogues thereof.